Header Logo

Connection

CHARLES CLEELAND to Rituximab

Back to Details
This is a "connection" page, showing publications CHARLES CLEELAND has written about Rituximab.
CHARLES CLEELAND
Connection Strength
0.101
Rituximab
  1. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.
    View in: PubMed
    Score: 0.101
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.